Sinopharm Holding and MedSci Announce Strategic Collaboration to Co-create the Future of Digital Medicine

General Manager, Global Procurement and Supply Chain Service Center, Sinopharm HoldingsLiu Tianyao,

Sun Chao, Deputy General Manager of MedSci, signed the agreement on behalf of both parties.

Liu Yong, President and Executive Director of Sinopharm Group; Chen Zhanyu, Vice President; Liu Tianyao, General Manager of the Global Procurement and Supply Chain Service Center; Fan Jie, Co-CEO of MedSci; Wan Zhifang, Vice President; Wang Shuai, Vice President; Wang Tianpei, Vice President of R&D; Sun Chao, Deputy General Manager; Wu Zhihua, Deputy General Manager; Liu Ce, Head of the Clinical Research Division; Lu Ruihua, Deputy General Manager of the Clinical Research Division; and representatives from the management teams of both companies attended and witnessed the signing ceremony. The two parties will engage in active cooperation in areas such as clinical research and digital marketing, jointly explore new models for digital business development, and promote high-quality industry growth.

Address by Liu Yong, President and Executive Director of Sinopharm Holdings

Liu Yong, President and Executive Director of Sinopharm Group Co., Ltd. (Sinopharm), stated that in active response to the State-owned Assets Supervision and Administration Commission’s (SASAC) requirements for advancing the digital transformation of state-owned enterprises and accelerating the construction of a Digital China, Sinopharm, as the largest commercial entity under China National Pharmaceutical Group Corporation (Sinopharm Group), will further leverage its robust supply chain services and marketing management capabilities during the 14th Five-Year Plan period. The company aims to accelerate its digitalization efforts and establish innovative service models.

As a leading service provider in China’s internet healthcare and biotechnology sectors, MedSci spans the entire healthcare industry value chain, connecting pharmaceutical companies, serving physicians, and benefiting patients. It has become a premier online professional platform for industry professionals to gain insights into sector developments and access cutting-edge medical knowledge. Today’s collaboration marks a new chapter for Sinopharm Holding in its digital business endeavors. We believe that through in-depth cooperation and mutual empowerment, both parties will drive high-quality development in the pharmaceutical and healthcare industries.

Address by Fan Jie, Co-CEO of MedSci

Fan Jie, Co-CEO of MedSci, stated that digital empowerment has become a key driver for pharmaceutical companies to reduce costs, improve efficiency, and achieve rapid growth in the healthcare industry. In particular, clinical research faces severe challenges in the current environment where pandemic control measures have become normalized.

MedSci boasts 4 million registered members, including 2.6 million registered physicians. Leveraging its extensive physician platform, robust digital clinical research capabilities, and a professional medical academic support team, MedSci provides clients with comprehensive innovative clinical research solutions.

MedSci eagerly anticipates deepening its collaboration with global leaders such as Sinopharm Holding. We are confident that, by integrating resources, both parties can drive industry innovation and jointly create a future for digital healthcare.

General Manager, Global Procurement and Supply Chain Service Center, Sinopharm HoldingsLiu Tianyao,

Group Photo of Sun Chao, Deputy General Manager of MedSci, at the Signing Ceremony

Liu Tianyao, General Manager of the Global Procurement and Supply Chain Service Center at Sinopharm Group, stated that Sinopharm would engage in extensive collaboration in clinical research services and digital marketing, leveraging respective strengths to align optimal resources. Through digital transformation, the company aims to build a digital platform.

Sun Chao, Deputy General Manager of MedSci, stated that MedSci has long been committed to clinical research services, data management, medical statistics, clinical training, and continuing education support. Meanwhile, by promoting the professional development of clinicians, advancing smart healthcare, and exploring innovative digital marketing models, MedSci has established a distinctive digital end-to-end service system.

Leveraging this strategic partnership, Sinopharm Group and MedSci complement each other’s strengths by combining Sinopharm’s robust channel and retail market capabilities with MedSci’s efficient, digitally driven medical academic expertise anchored in its premier physician platform. Together, they aim to elevate awareness, diagnosis, and treatment standards for relevant disease areas in China, enabling more patients to access high-quality pharmaceuticals and healthcare services, thereby contributing to the realization of the “Healthy China” strategy.

Sinopharm Group Co., Ltd. was established in January 2003 and listed in Hong Kong in September 2009 (01099.HK). As a core enterprise of China National Pharmaceutical Group Corporation—the only central pharmaceutical and health industry group under the direct administration of the State-owned Assets Supervision and Administration Commission of the State Council with life and health as its main business—it owns two A-share listed companies, Sinopharm Holding and Sinopharm Accord, along with more than 1,000 other subsidiaries. It has developed into China’s leading distributor and retailer of pharmaceuticals, healthcare products, and medical devices, as well as a leading supply chain service provider. The company has formed an integrated industrial chain featuring the synergistic development of diversified business sectors, including product distribution and delivery, retail and clinical services, chemical reagents, medical devices, and medical health services, constituting the most comprehensive pharmaceutical and health ecosystem in China. Over the years, Sinopharm Group has continuously advanced the decentralization of its distribution network and strengthened its network layout. Its distribution and delivery networks for pharmaceuticals and medical devices cover all 31 provinces, municipalities, and autonomous regions across China, ranking first in market share in 20 provinces, with a coverage rate of 97% at the prefecture-level administrative divisions and 98% at the county-level administrative divisions. In 2021, it ranked 22nd on the Fortune China 500 list and 1st in the pharmaceutical industry on the Top 500 Most Valuable Chinese Brands list.

MedSci leverages its professional online physician platform, built over more than a decade, to connect physicians, patients, and pharmaceutical and medical device companies through big data and artificial intelligence technologies. It provides digital solutions that empower the healthcare ecosystem and improve the quality of care. Its business offerings include physician platform solutions, real-world study solutions, and precision omnichannel marketing solutions. Covering specialized services such as pharmaceutical marketing consulting, medical affairs enablement, and multichannel academic dissemination, MedSci delivers one-stop digital solutions in medical affairs, marketing, market access, and communications for pharmaceutical and medical device enterprises.